DSIP (5 mg Vial) Dosage Protocol

DSIP Dosage Chart

DSIP (Delta Sleep-Inducing Peptide) is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols, usually before bedtime. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
  • Typical daily range: 100–300 mcg once daily (gradual titration); advanced up to 500 mcg.
  • Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
DSIP 5mg vial - DSIP dosage protocol

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide (9 amino acids) first isolated from rabbit brain tissue and studied for its effects on sleep architecture and stress modulation[1][2]. Research indicates DSIP may promote delta-wave (slow-wave) sleep, modulate cortisol and ACTH levels, and exhibit stress-protective properties[3][4]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Week 1 100 mcg 6 units (0.06 mL)
Week 2 150 mcg 9 units (0.09 mL)
Week 3 200 mcg 12 units (0.12 mL)
Weeks 4–8 250–300 mcg 15–18 units (0.15–0.18 mL)
Week 5 350–400 mcg 21–24 units (0.21–0.24 mL)
Weeks 6–8+ 400–500 mcg 24–30 units (0.24–0.30 mL)

Frequency: Inject once daily subcutaneously, typically in the evening before bedtime[5][6]. For ≤10-unit (≤0.10 mL) administrations (Weeks 1–2), consider 30- or 50-unit insulin syringes for improved readability.

Note: Advanced dosing (beyond 300 mcg) is based on anecdotal experience; formal human studies have primarily used doses up to ~300 mcg daily[7]. Use the minimum effective dose and increase only if needed.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
n

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

n

Supplies Needed

Plan based on an 8–12 week daily protocol with gradual titration.

  • Peptide Vials (DSIP, 5 mg each):
    • 8 weeks at ~200 mcg/day avg ≈ 2–3 vials
    • 12 weeks at ~200 mcg/day avg ≈ 3–4 vials
    • 12 weeks at ~300 mcg/day avg ≈ 5–6 vials
  • Insulin Syringes (U-100):
    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
    • 3 vials: 9 mL1 × 10 mL bottle
    • 5 vials: 15 mL2 × 10 mL bottles
    • 6 vials: 18 mL2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes

Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support healthy sleep architecture and stress modulation over time[3][4].
  • Schedule: Daily subcutaneous injections for 4–8 weeks (extend to 12 weeks if desired).
  • Dose Range: 100–300 mcg daily with gradual titration; advanced up to 500 mcg.
  • Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

  • Start: 100 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated.
  • Target: 250–300 mcg daily by Weeks 4–8.
  • Frequency: Once per day (subcutaneous), typically before bedtime.
  • Cycle Length: 4–8 weeks; optional extension to 12 weeks with periodic breaks.
  • Timing: Evening administration preferred; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[8].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~4 weeks and avoid freeze–thaw[9].
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • Some research suggests DSIP effects may persist for multiple nights after dosing[2]; adjust frequency as needed.

How This Works

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) was first characterized in 1977 as a sleep-modulating factor isolated from rabbit brain[1]. Mechanistic studies suggest DSIP may influence sleep by modulating GABAergic transmission and interacting with opioid receptor systems[10]. Research indicates it can increase delta-wave (slow-wave) sleep duration without significantly altering REM sleep architecture[3]. Beyond sleep, DSIP has demonstrated stress-protective and adaptogenic properties in various models, potentially through modulation of the hypothalamic-pituitary-adrenal axis[4][11].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • May promote deeper, more restorative slow-wave sleep and improve subjective sleep quality[3][5].
  • Research suggests potential stress-protective and anxiolytic-like effects[4][11].
  • Some studies indicate DSIP does not induce pharmacological tolerance with continued use[2].
  • Generally well tolerated in human studies; occasional mild injection-site reactions may occur with subcutaneous administration.
  • Limited long-term safety data; periodic breaks are recommended as a precaution[6].

Lifestyle Factors

Complementary strategies for best outcomes.

  • Maintain consistent sleep-wake schedules to reinforce circadian rhythms.
  • Limit blue light exposure and stimulants (caffeine, nicotine) in the hours before bed.
  • Create a cool, dark, quiet sleep environment.
  • Incorporate regular physical activity, ideally earlier in the day.
  • Manage stress through relaxation techniques (meditation, deep breathing).

Injection Technique

General subcutaneous guidance from clinical best-practice resources[12].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][13].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
  • Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy[13].

Important Note

This content is for educational purposes only and is not medical advice.

References

  • Schoenenberger GA, Monnier M (1977)
    — Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA
  • European Journal of Anaesthesiology (2001)
    — Delta sleep-inducing peptide: editorial review of mechanisms and clinical context
  • Schneider-Helmert D, Schoenenberger GA (1983)
    — Effects of DSIP in man: multifunctional psychophysiological properties. Neuropsychobiology
  • Sudakov KV et al. (2004)
    — Delta-sleep-inducing peptide sequelae: stress protective effect. Ann N Y Acad Sci
  • Schneider-Helmert D (1981)
    — Acute and delayed effects of DSIP on human sleep behavior. Int J Clin Pharmacol Ther Toxicol
  • Graf MV, Kastin AJ (1984)
    — Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev
  • Iyer KS et al. (1988)
    — Sleep-inducing effect of low doses of DSIP in rats. Indian J Exp Biol
  • Manning MC et al. (2010)
    — Stability of protein pharmaceuticals: an update. Pharm Res
  • Wang W (2000)
    — Lyophilization and development of solid protein pharmaceuticals. Int J Pharm
  • Yehuda S, Carasso RL (1988)
    — DSIP: brain mechanisms and function. Int J Neurosci
  • Khvatova EM et al. (2003)
    — Delta sleep-inducing peptide: effect on oxidative stress in brain during different models. Biull Eksp Biol Med
  • CDC
    — Vaccine administration: subcutaneous route (angle/site; no aspiration)
  • NCBI Bookshelf
    — Medication Administration: Subcutaneous Injections (Open RN Nursing Skills)
  • Pure Lab Peptides
    — DSIP (5 mg) product page (quality and batch documentation)